PanGIA Biotech

Executive Summary

PanGIA Biotech is a San Diego-based diagnostics company pioneering a non-invasive, AI-powered platform for early cancer detection. Founded in 2018, the company leverages colorimetric biomolecular profiling of urine samples combined with machine learning algorithms to identify disease signatures. This approach offers a low-cost, accessible alternative to traditional screening methods, potentially enabling earlier intervention and improved outcomes. PanGIA's initial focus is on a multi-cancer detection pipeline, with prostate cancer as its lead indication. The platform's ability to detect multiple cancers from a single urine sample positions it as a disruptive force in the liquid biopsy market, addressing the critical need for simple, scalable screening solutions.

Upcoming Catalysts (preview)

• Q1 2027Completion of clinical validation study for prostate cancer detection70% success
• Q3 2026FDA breakthrough device designation60% success
• Q4 2026Strategic partnership with a major diagnostic company50% success